Table 4.
Rate, % (proportion) | |
---|---|
Achieved 400 mg daily | 81% (137/169) |
Maintained 400 mg daily | 65% (108/166) |
Required Dose Reduction | 29% (51/177) |
Required Dose Interruption Duration median (range) |
32% (58/181) 7 days (1–132) |
Venetoclax Discontinuation Rate | 40% (119/297) |
Venetoclax Discontinued for AE | 7.7% (23/297) |